Cardiac Magnetic Resonance-Guided Ventricular Tachycardia Substrate Ablation
Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved..
OBJECTIVES: This study assessed the feasibility and potential benefit of performing ventricular tachycardia (VT) substrate ablation procedures guided by cardiac magnetic resonance (CMR)-derived pixel signal intensity (PSI) maps.
BACKGROUND: CMR-aided VT ablation using PSI maps from late gadolinium enhancement-CMR (LGE-CMR), together with electroanatomical map (EAM) information, has been shown to improve outcomes of VT substrate ablation.
METHODS: Eighty-four patients with scar-dependent monomorphic VT who underwent substrate ablation were included in the study. In the last 28 (33%) consecutive patients, the procedure was guided by CMR. Procedural data, as well as acute and follow-up outcomes, were compared between patients who underwent guided CMR and 2 control groups: 1) patients who had PSI maps were available but the EAM was acquired and used to select the ablation targets (CMR aided); and 2) patients with no CMR-derived PSI maps available (no CMR).
RESULTS: Mean procedure duration was lower in CMR-guided substrate ablation compared with CMR-aided and no CMR (107 ± 59 min vs. 203 ± 68 min and 227 ± 52 min; p < 0.001 for both comparisons). CMR-guided ablation required less fluoroscopy time than CMR-aided ablation and no CMR (10 ± 4 min vs. 23 ± 11 min and 20 ± 9 min, respectively; p < 0.001 for both comparisons) and less radiofrequency time (15 ± 8 min vs. 20 ± 15 min and 26 ± 10 min; p = 0.16 and p < 0.001, respectively). After substrate ablation, VT inducibility was lower in CMR-guided ablation compared with CMR-aided ablation and no CMR (18% vs. 32% and 46%; p = 0.35 and p = 0.04, respectively), without significant differences in complications. After 12 months, VT recurrence was lower in those who underwent CMR-guided ablation compared with no CMR (log-rank: 0.019), with no differences with CMR-aided ablation.
CONCLUSIONS: CMR-guided VT ablation is feasible and safe, significantly reduces the procedural, fluoroscopy, and radiofrequency times, and is associated with a higher noninducibility rate and lower VT recurrence after substrate ablation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
JACC. Clinical electrophysiology - 6(2020), 4 vom: 13. Apr., Seite 436-447 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Soto-Iglesias, David [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
AU0V1LM3JT |
|---|
| Anmerkungen: |
Date Completed 18.08.2021 Date Revised 18.08.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jacep.2019.11.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM309114225 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309114225 | ||
| 003 | DE-627 | ||
| 005 | 20231225133211.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jacep.2019.11.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1030.xml |
| 035 | |a (DE-627)NLM309114225 | ||
| 035 | |a (NLM)32327078 | ||
| 035 | |a (PII)S2405-500X(19)30910-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Soto-Iglesias, David |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cardiac Magnetic Resonance-Guided Ventricular Tachycardia Substrate Ablation |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.08.2021 | ||
| 500 | |a Date Revised 18.08.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a OBJECTIVES: This study assessed the feasibility and potential benefit of performing ventricular tachycardia (VT) substrate ablation procedures guided by cardiac magnetic resonance (CMR)-derived pixel signal intensity (PSI) maps | ||
| 520 | |a BACKGROUND: CMR-aided VT ablation using PSI maps from late gadolinium enhancement-CMR (LGE-CMR), together with electroanatomical map (EAM) information, has been shown to improve outcomes of VT substrate ablation | ||
| 520 | |a METHODS: Eighty-four patients with scar-dependent monomorphic VT who underwent substrate ablation were included in the study. In the last 28 (33%) consecutive patients, the procedure was guided by CMR. Procedural data, as well as acute and follow-up outcomes, were compared between patients who underwent guided CMR and 2 control groups: 1) patients who had PSI maps were available but the EAM was acquired and used to select the ablation targets (CMR aided); and 2) patients with no CMR-derived PSI maps available (no CMR) | ||
| 520 | |a RESULTS: Mean procedure duration was lower in CMR-guided substrate ablation compared with CMR-aided and no CMR (107 ± 59 min vs. 203 ± 68 min and 227 ± 52 min; p < 0.001 for both comparisons). CMR-guided ablation required less fluoroscopy time than CMR-aided ablation and no CMR (10 ± 4 min vs. 23 ± 11 min and 20 ± 9 min, respectively; p < 0.001 for both comparisons) and less radiofrequency time (15 ± 8 min vs. 20 ± 15 min and 26 ± 10 min; p = 0.16 and p < 0.001, respectively). After substrate ablation, VT inducibility was lower in CMR-guided ablation compared with CMR-aided ablation and no CMR (18% vs. 32% and 46%; p = 0.35 and p = 0.04, respectively), without significant differences in complications. After 12 months, VT recurrence was lower in those who underwent CMR-guided ablation compared with no CMR (log-rank: 0.019), with no differences with CMR-aided ablation | ||
| 520 | |a CONCLUSIONS: CMR-guided VT ablation is feasible and safe, significantly reduces the procedural, fluoroscopy, and radiofrequency times, and is associated with a higher noninducibility rate and lower VT recurrence after substrate ablation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a cardiac magnetic resonance | |
| 650 | 4 | |a conducting channels | |
| 650 | 4 | |a image-guided ablation | |
| 650 | 4 | |a substrate ablation | |
| 650 | 7 | |a Contrast Media |2 NLM | |
| 650 | 7 | |a Gadolinium |2 NLM | |
| 650 | 7 | |a AU0V1LM3JT |2 NLM | |
| 700 | 1 | |a Penela, Diego |e verfasserin |4 aut | |
| 700 | 1 | |a Jáuregui, Beatriz |e verfasserin |4 aut | |
| 700 | 1 | |a Acosta, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández-Armenta, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Linhart, Markus |e verfasserin |4 aut | |
| 700 | 1 | |a Zucchelli, Giulio |e verfasserin |4 aut | |
| 700 | 1 | |a Syrovnev, Vladimir |e verfasserin |4 aut | |
| 700 | 1 | |a Zaraket, Fatima |e verfasserin |4 aut | |
| 700 | 1 | |a Terés, Cheryl |e verfasserin |4 aut | |
| 700 | 1 | |a Perea, Rosario J |e verfasserin |4 aut | |
| 700 | 1 | |a Prat-González, Susana |e verfasserin |4 aut | |
| 700 | 1 | |a Doltra, Ada |e verfasserin |4 aut | |
| 700 | 1 | |a Ortiz-Pérez, José T |e verfasserin |4 aut | |
| 700 | 1 | |a Bosch, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Camara, Oscar |e verfasserin |4 aut | |
| 700 | 1 | |a Berruezo, Antonio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JACC. Clinical electrophysiology |d 2015 |g 6(2020), 4 vom: 13. Apr., Seite 436-447 |w (DE-627)NLM251686930 |x 2405-5018 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2020 |g number:4 |g day:13 |g month:04 |g pages:436-447 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jacep.2019.11.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2020 |e 4 |b 13 |c 04 |h 436-447 | ||